Germany-based Exciva, a clinical-stage biotech company developing a novel therapeutic compound for treating agitation and aggression in Alzheimer’s disease, announced that it has raised €9M in its Series A round of funding.
Investors in this round
The round was led by Andera Partners. LBBW Venture Capital and Cure8 also participated in the round.
Speaking about the startup, Raphaël Wisniewski, partner at Andera Partners says, “Exciva is taking a uniquely promising approach to addressing symptoms in Alzheimer’s disease; a condition which still has huge unmet medical needs.”
“These proceeds will be used to complete Phase I with the goal of starting Phase II in the next 18 months,” adds Sofia Ioannidou, partner at Andera Partners.
Innovative treatment to address symptoms of Alzheimer’s patients
According to a statement from Exciva, the behavioural symptoms of Alzheimer’s disease (AD) are chronic. The progressive neurological disorders include a number of symptoms such as agitation/aggression, sleep and eating disorders, irritability, depression, anxiety and hallucinations. These symptoms come with ageing and appear in clusters.
Prevalence of AD and hence behavioural and psychological symptoms are growing with aging societies. And as of now, no specific medication has been registered to treat behavioural and psychological symptoms.
This is where Exciva looks to make a difference.
Founded in 2016 and led by CEO François Conquet, Exciva is a biopharmaceutical company focused on delivering a new scientific approach that fully integrates molecular, behavioural, and chemistry technologies to address behavioural and psychological symptoms in Alzheimer’s disease and other dementias.
The company offers a targeted drug rescue program that involves pharmaceutical research and development. This program helps in developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using such compositions. This access to the program enables the healthcare industry to rescue and reuse approved drugs for new indications and new uses.
Capital utilisation
Francois Conquet says, “Our lead candidate, Deraphan, combines two compounds which have separately demonstrated a safety profile as well as an efficient activity in patients living with behavioral conditions. With this investment, we can look forward to advancing this product, the combination of these two compounds, through to the start of Phase II.”
Exciva reports that this product has the potential to treat behavioural and psychological symptoms in Alzheimer disease patients.
01
From employee advocacy to social selling: Oktopost founder Daniel Kushner on the future of B2B marketing